Treatment of relapsed small cell lung cancer (Q34323183)

1 August 2017

1 reference

title

Treatment of relapsed small cell lung cancer (English)

1 reference

1 August 2017

1

Postmus PE

1 reference

1 August 2017

Smit EF

2

1 reference

1 August 2017

publication date

1 April 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

28

1 reference

1 August 2017

issue

2 Suppl 4

1 reference

1 August 2017

page(s)

48-52

1 reference

Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Second-line chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Small-Cell Carcinoma of Lung: Reinduction Therapy After Late Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Reinduction chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Second-line chemotherapy and its evaluation in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Response to Thoracic Radiotherapy in Patients with Small Cell Carcinoma of the Lung After Failure of Combination Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2801%2990079-X

7 January 2021

10.1016/S0093-7754(01)90079-X

Identifiers

DOI

1 reference

1 August 2017

1 reference